Appendix 3: Test/retest reliability of FACIT-Fatigue in patients with PsA. (DOCX 12.4 kb
Additional file 1: Additional Table 1a. Characteristics of the UPREAL-PsA study patients subgroups a...
Table S1. Psoriasis disease activity at enrollment; PSOLAR psoriasis patients. (DOCX 26Â kb
Appendix A. ICD codes for disease to be excluded. Appendix B. Dosage regimen of included BTs. Append...
Table S1. Test/retest reliability of FACIT-Fatigue in patients with PsA. (DOCX 26âkb
Table S1. SF-36 domain scores by MDA responder status, mean (SD) and p-values. (DOCX 15 kb
Additional file 1. Supplemental information regarding measures, methods, and results
Table S1. Disease activity and function before and after weight loss treatment in the 29 patients wi...
Table S3. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...
Table S1. Adjusted mean change from baseline in SF-36 individual domains at weeks 16 (all patients) ...
Appendix 1. Search strategy. Appendix 2. Quality criteria to appraise reported measurement propertie...
Table S1. Factor loadings for PACIC (promax rotation) - four-factor model. Table S2. Factor loadings...
Table S1. Least squares (LS) mean change from baseline in composite endpoint scores (full analysis s...
Table S1. E/M Codes. Table S2. Patient perception of treatment effectiveness stratified according to...
Table S2. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...
Table S2. Change from baseline in composite endpoint scores by minimal disease activity (MDA) respon...
Additional file 1: Additional Table 1a. Characteristics of the UPREAL-PsA study patients subgroups a...
Table S1. Psoriasis disease activity at enrollment; PSOLAR psoriasis patients. (DOCX 26Â kb
Appendix A. ICD codes for disease to be excluded. Appendix B. Dosage regimen of included BTs. Append...
Table S1. Test/retest reliability of FACIT-Fatigue in patients with PsA. (DOCX 26âkb
Table S1. SF-36 domain scores by MDA responder status, mean (SD) and p-values. (DOCX 15 kb
Additional file 1. Supplemental information regarding measures, methods, and results
Table S1. Disease activity and function before and after weight loss treatment in the 29 patients wi...
Table S3. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...
Table S1. Adjusted mean change from baseline in SF-36 individual domains at weeks 16 (all patients) ...
Appendix 1. Search strategy. Appendix 2. Quality criteria to appraise reported measurement propertie...
Table S1. Factor loadings for PACIC (promax rotation) - four-factor model. Table S2. Factor loadings...
Table S1. Least squares (LS) mean change from baseline in composite endpoint scores (full analysis s...
Table S1. E/M Codes. Table S2. Patient perception of treatment effectiveness stratified according to...
Table S2. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...
Table S2. Change from baseline in composite endpoint scores by minimal disease activity (MDA) respon...
Additional file 1: Additional Table 1a. Characteristics of the UPREAL-PsA study patients subgroups a...
Table S1. Psoriasis disease activity at enrollment; PSOLAR psoriasis patients. (DOCX 26Â kb
Appendix A. ICD codes for disease to be excluded. Appendix B. Dosage regimen of included BTs. Append...
DOI
Add to ORKG